Opinion|Videos|October 7, 2023
AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma
Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.
Advertisement
Episodes in this series
Advertisement
Related to this article
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
5